<DOC>
	<DOCNO>NCT01813435</DOCNO>
	<brief_summary>After stent procedure , common practice prescribe anti-platelet medication prevent blood clotting . The main objective study determine good medication strategy prevent blood clot time minimise number complication . There two medication strategy : - Study group : Dual anti-platelet therapy ( ticagrelor combine aspirin ) 1 month , ticagrelor alone another 23 month OR - Control group : Standard treatment , dual anti-platelet therapy ( ticagrelor clopidogrel combine aspirin ) 12 month , aspirin alone indefinitely</brief_summary>
	<brief_title>GLOBAL LEADERS : A Clinical Study Comparing Two Forms Anti-platelet Therapy After Stent Implantation</brief_title>
	<detailed_description>The study objective determine all-comers patient undergo PCI standardise treatment ( include BioMatrix family drug-eluting stent bivalirudin ) , whether treatment 1 month ticagrelor aspirin follow 23 month ticagrelor monotherapy superior respect composite all-cause mortality non-fatal new Q-wave MI compare treatment 12 month standard dual anti platelet therapy ( DAPT ) follow aspirin monotherapy . The study design investigator-initiated , prospective randomise , multi-centre , multi-national , open-label trial conduct approximately 60-80 interventional cardiology centre Europe , North America , South America Asia-Pacific . Patients randomise 1:1 ratio study reference treatment strategy . Randomisation occur time index procedure prior PCI . Subjects stratify accord centre accord clinical presentation ( Stable Coronary Artery Disease ( CAD ) v . Acute Coronary Syndrome ( ACS ) ) . All patient follow period 2 year .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>`` All comer '' patient 1 . Age ≥18 year ; 2 . Presence one coronary artery stenoses 50 % native coronary artery saphenous venous arterial bypass conduit suitable coronary stent implantation . The vessel reference vessel diameter least 2.25 mm ( limitation number treat lesion , vessel , lesion length ) ; 3 . Able provide inform consent willing participate 2 year follow period . 1 . Known intolerance aspirin , P2Y12 inhibitor , bivalirudin , stainless steel biolimus ; 2 . Known intake strong CYP3A4 inhibitor ( e.g. , ketoconazole , clarithromycin , nefazodone , ritonavir , atazanavir ) , coadministration may lead substantial increase exposure ticagrelor ; 3 . Known moderate severe hepatic impairment ( alanineaminotransferase ≥ 3 x ULN ) ; 4 . Planned surgery , include CABG stag procedure ( hybrid ) within 12 month index procedure , unless dual antiplatelet therapy maintain throughout perisurgical period ; 5 . Need chronic oral anticoagulation therapy ; 6 . Active major bleed major surgery within last 30 day ; 7 . Known history intracranial haemorrhagic stroke intracranial aneurysm ; 8 . Known stroke ( type ) within last 30 day ; 9 . Known pregnancy time randomisation ; 10 . Female breastfeeding time randomisation ; 11 . Currently participate another trial yet primary endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>CAD</keyword>
	<keyword>ACS</keyword>
	<keyword>All comer</keyword>
	<keyword>DAPT</keyword>
	<keyword>PCI</keyword>
</DOC>